Literature DB >> 31201206

TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data.

Mei-Ju May Chen1, Jun Li1, Yumeng Wang1, Rehan Akbani1, Yiling Lu2, Gordon B Mills2,3, Han Liang4,2.   

Abstract

Reverse-phase protein arrays represent a powerful functional proteomics approach to characterizing cell signaling pathways and understanding their effects on cancer development. Using this platform, we have characterized ∼8,000 patient samples of 32 cancer types through The Cancer Genome Atlas and built a widely used, open-access bioinformatic resource, The Cancer Proteome Atlas (TCPA). To maximize the utility of TCPA, we have developed a new module called "TCGA Pan-Cancer Analysis," which provides comprehensive protein-centric analyses that integrate protein expression data and other TCGA data across cancer types. We further demonstrate the value of this module by examining the correlations of RPPA proteins with significantly mutated genes, assessing the predictive power of somatic copy-number alterations, DNA methylation, and mRNA on protein expression, inferring the regulatory effects of miRNAs on protein expression, constructing a co-expression network of proteins and pathways, and identifying clinically relevant protein markers. This upgraded TCPA (v3.0) will provide the cancer research community with a more powerful tool for studying functional proteomics and making translational impacts.
© 2019 Chen et al.

Entities:  

Keywords:  Bioinformatics Software; Biomarker: Prognostic; Cancer Biology; Functional Proteomics; Gene Expression; Pan-Cancer Analysis; Pathway Analysis; Protein Array; Proteogenomics; TCGA

Mesh:

Substances:

Year:  2019        PMID: 31201206      PMCID: PMC6692772          DOI: 10.1074/mcp.RA118.001260

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  23 in total

1.  Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Authors:  Jun Li; Wei Zhao; Rehan Akbani; Wenbin Liu; Zhenlin Ju; Shiyun Ling; Christopher P Vellano; Paul Roebuck; Qinghua Yu; A Karina Eterovic; Lauren A Byers; Michael A Davies; Wanleng Deng; Y N Vashisht Gopal; Guo Chen; Erika M von Euw; Dennis Slamon; Dylan Conklin; John V Heymach; Adi F Gazdar; John D Minna; Jeffrey N Myers; Yiling Lu; Gordon B Mills; Han Liang
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

2.  Development of a robust classifier for quality control of reverse-phase protein arrays.

Authors:  Zhenlin Ju; Wenbin Liu; Paul L Roebuck; Doris R Siwak; Nianxiang Zhang; Yiling Lu; Michael A Davies; Rehan Akbani; John N Weinstein; Gordon B Mills; Kevin R Coombes
Journal:  Bioinformatics       Date:  2014-11-06       Impact factor: 6.937

3.  Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.

Authors:  Belen Fernandez-Garcia; Noemí Eiró; Laura Marín; Salomé González-Reyes; Luis O González; Maria Luz Lamelas; Francisco J Vizoso
Journal:  Histopathology       Date:  2013-11-28       Impact factor: 5.087

4.  Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas.

Authors:  Jun Li; Rehan Akbani; Wei Zhao; Yiling Lu; John N Weinstein; Gordon B Mills; Han Liang
Journal:  Cancer Res       Date:  2017-11-01       Impact factor: 12.701

5.  Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.

Authors:  Chunzhang Yang; Ashok R Asthagiri; Rajiv R Iyer; Jie Lu; David S Xu; Alexander Ksendzovsky; Roscoe O Brady; Zhengping Zhuang; Russell R Lonser
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

Review 6.  MicroRNAs: target recognition and regulatory functions.

Authors:  David P Bartel
Journal:  Cell       Date:  2009-01-23       Impact factor: 41.582

7.  MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer.

Authors:  Chen Liang; Xing Zhang; Hui-Min Wang; Xiao-Min Liu; Xin-Ju Zhang; Bo Zheng; Guang-Ren Qian; Zhong-Liang Ma
Journal:  Cell Death Dis       Date:  2017-05-04       Impact factor: 8.469

8.  Fibronectin-guided migration of carcinoma collectives.

Authors:  Sandeep Gopal; Laurence Veracini; Dominique Grall; Catherine Butori; Sébastien Schaub; Stéphane Audebert; Luc Camoin; Emilie Baudelet; Agata Radwanska; Stéphanie Beghelli-de la Forest Divonne; Shelia M Violette; Paul H Weinreb; Samah Rekima; Marius Ilie; Anne Sudaka; Paul Hofman; Ellen Van Obberghen-Schilling
Journal:  Nat Commun       Date:  2017-01-19       Impact factor: 14.919

9.  KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.

Authors:  Jihua Han; Fengyue Wang; Yaliang Lan; Jiabei Wang; Chunlei Nie; Yingjian Liang; Ruipeng Song; Tongsen Zheng; Shangha Pan; Tiemin Pei; Changming Xie; Guangchao Yang; Xirui Liu; Mingxi Zhu; Yan Wang; Yao Liu; Fanzheng Meng; Yifeng Cui; Bo Zhang; Yufeng Liu; Xianzhi Meng; Jiewu Zhang; Lianxin Liu
Journal:  Oncogene       Date:  2018-08-16       Impact factor: 9.867

10.  Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.

Authors:  Yumeng Wang; Xiaoyan Xu; Dejan Maglic; Michael T Dill; Kamalika Mojumdar; Patrick Kwok-Shing Ng; Kang Jin Jeong; Yiu Huen Tsang; Daniela Moreno; Venkata Hemanjani Bhavana; Xinxin Peng; Zhongqi Ge; Hu Chen; Jun Li; Zhongyuan Chen; Huiwen Zhang; Leng Han; Di Du; Chad J Creighton; Gordon B Mills; Fernando Camargo; Han Liang
Journal:  Cell Rep       Date:  2018-10-30       Impact factor: 9.423

View more
  12 in total

1.  Proteomics Is Not an Island: Multi-omics Integration Is the Key to Understanding Biological Systems.

Authors:  Bing Zhang; Bernhard Kuster
Journal:  Mol Cell Proteomics       Date:  2019-08-09       Impact factor: 5.911

Review 2.  Proteomics advances for precision therapy in ovarian cancer.

Authors:  Marilyne Labrie; Nicholas D Kendsersky; Hongli Ma; Lydia Campbell; Jennifer Eng; Koei Chin; Gordon B Mills
Journal:  Expert Rev Proteomics       Date:  2019-09-13       Impact factor: 3.940

3.  Comprehensive analysis of novel prognosis-related proteomic signature effectively improve risk stratification and precision treatment for patients with cervical cancer.

Authors:  Xiaoyu Ji; Guangdi Chu; Yulong Chen; Jinwen Jiao; Teng Lv; Qin Yao
Journal:  Arch Gynecol Obstet       Date:  2022-06-17       Impact factor: 2.344

4.  Deciphering specific miRNAs in brain tumors: a 5-miRNA signature in glioblastoma.

Authors:  João Basso; Marco G Paggi; Ana Fortuna; Carla Vitorino; Rui Vitorino
Journal:  Mol Genet Genomics       Date:  2022-02-17       Impact factor: 3.291

5.  The Prediction of a 3-Protein-Based Model on the Prognosis of Head and Neck Squamous Cell Carcinoma.

Authors:  Xiaoting Chen; Kaiyi Wong; Yixuan Li; Zhong Guan
Journal:  Comput Math Methods Med       Date:  2022-06-17       Impact factor: 2.809

6.  Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations.

Authors:  Wang Yang; Naifei Chen; Lingyu Li; Xiao Chen; Xiangliang Liu; Yongfei Zhang; Jiuwei Cui
Journal:  Lung Cancer (Auckl)       Date:  2020-09-07

7.  Identification of a Novel Protein-Based Signature to Improve Prognosis Prediction in Renal Clear Cell Carcinoma.

Authors:  Guangdi Chu; Ting Xu; Guanqun Zhu; Shuaihong Liu; Haitao Niu; Mingxin Zhang
Journal:  Front Mol Biosci       Date:  2021-03-25

8.  Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes.

Authors:  Maria R Jubran; Daniela Vilenski; Efrat Flashner-Abramson; Efraim Shnaider; Swetha Vasudevan; Ariel M Rubinstein; Amichay Meirovitz; Shay Sharon; David Polak; Nataly Kravchenko-Balasha
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.556

9.  Development of a five-protein signature for predicting the prognosis of head and neck squamous cell carcinoma.

Authors:  Xinyuan Zhao; Xianwen Liu; Li Cui
Journal:  Aging (Albany NY)       Date:  2020-10-13       Impact factor: 5.682

10.  Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Sun Young Yim; Sang Hee Kang; Ji-Hyun Shin; Yun Seong Jeong; Bo Hwa Sohn; Soon Ho Um; Ju-Seog Lee
Journal:  Cells       Date:  2020-09-01       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.